TLR4 Activation Assay with NETs and Anti-CarP Antibodies

PRIMARY OUTCOME

enhanced TLR4 activation by NETs exposed to anti-CarP antibodies

EXPECTED OUTCOMES

## Expected Outcomes ### Primary Outcomes 1. **NET-induced TLR4 activation:** Dose-dependent NF-κB activation with EC50 ~5-10 µg/mL NETs 2. **Anti-CarP enhancement:** Pre-incubation with anti-CarP increases NET-TLR4 activation 2-3 fold 3. **TLR4 specificity:** TAK-242 reduces activation by ≥80% 4. **Cytokine release:** IL-8 and TNF-α detected in supernatant ### Secondary Outcomes - Different NETosis inducers (PMA vs ionomycin) may produce different potency - Carbamylated proteins in NETs identified by western blot or mass spectrometry - Correlation between NET DNA content and TLR4 activation ### Null Result Interpretation - If no activation, verify TLR4 cell line responsiveness (LPS positive control must work) - May need higher NET concentrations or longer incubation - Consider alternative TLRs (TLR2, TLR9 for DNA component)

SUCCESS CRITERIA

## Success Criteria ### Primary - [ ] NET quality: DNA > 500 ng/mL, neutrophil elastase activity confirmed - [ ] Anti-CarP specificity: ELISA shows ≥10-fold binding to CarP vs BSA - [ ] TLR4 activation: ≥3-fold NF-κB reporter increase at 10 µg/mL NETs - [ ] TAK-242 inhibition: ≥80% reduction confirms TLR4 specificity - [ ] Cytokine release: IL-8 ≥ 100 pg/mL in supernatant ### Secondary - [ ] Dose-response: EC50 calculated for NETs and anti-CarP synergy - [ ] DNase control: reduces but may not abolish activation - [ ] Non-TLR4 HEK293 control: no activation (confirms TLR4 dependence) ### Technical Quality Gates - [ ] TLR4 cell line verified: LPS positive control works - [ ] Isotype antibody control: no non-specific activation - [ ] No endotoxin contamination in reagents (LAL test) - [ ] ≥3 independent neutrophil donors

PROTOCOL

## Protocol: TLR4 Activation Assay with Neutrophil Extracellular Traps (NETs) and Anti-Carbamylated Protein (Anti-CarP) Antibodies ### Study Design In vitro assay examining whether NETs containing carbamylated proteins activate TLR4 signaling in HEK293-TLR4 reporter cells, and whether anti-CarP antibodies modulate this activation. ### Components 1. **NETosis induction:** - Neutrophils isolated from healthy donor peripheral blood (Ficoll gradient) - Activate with PMA (100 nM) or ionomycin (1 µM) for 4 hours - Collect NETs in supernatant, verify by DNA quantification (PicoGreen) and neutrophil elastase activity 2. **Anti-CarP antibodies:** - Use commercial anti-CarP antibody (e.g., from rheumatoid arthritis patient serum or monoclonal) - Confirm specificity: ELISA with carbamylated vs non-modified BSA 3. **HEK293-TLR4 reporter cells:** - HEK-Blue-hTLR4 cells (Invivogen) or stable transfected HEK293 with NF-κB-luciferase reporter + hTLR4 - Maintain in DMEM + 10% FBS + blasticidin (for selection maintenance) ### Co-treatment Experiment 1. Seed HEK293-TLR4 cells (50,000 cells/well in 96-well) 2. Stimulate with: - NETs alone (various concentrations: 1, 5, 10 µg/mL DNA content) - Anti-CarP antibody alone (1, 5, 10 µg/mL) - NETs + anti-CarP antibody (pre-incubated 30 min at RT) - LPS (100 ng/mL) as positive control - Ultrapure LPS (E. coli) for TLR4 specificity 3. Incubate 6-24 hours ### Readouts 1. **NF-κB activation:** - SEAP reporter (HEK-Blue detection medium, read at 650 nm) - OR luciferase reporter (One-Glo assay) 2. **TLR4 specificity:** - Include HEK293 cells without TLR4 as negative control - Use TLR4 antagonist (TAK-242, 1 µM) to block responses 3. **Signaling pathways:** - Western blot: pIKK, pIκBα, p65 phosphorylation - Cytokine release: ELISA for IL-8, TNF-α in supernatant ### Controls - **Negative control:** Untreated cells, isotype antibody control - **Positive control:** LPS (100 ng/mL) or PAM3CSK4 (TLR2/1 agonist) - **Specificity control:** TAK-242 (TLR4 inhibitor) + stimulus - **NET controls:** Neutrophil lysate (non-NET components), DNase-treated NETs ### Expected Outcomes 1. NETs activate TLR4 in dose-dependent manner (DNA and protein components) 2. Anti-CarP antibodies enhance NET-TLR4 activation (crosslinking/triggering) 3. TAK-242 blocks NET-induced activation (confirms TLR4 specificity) 4. DNase treatment reduces but may not abolish activation (protein component) ### Success Criteria - [ ] NETs verified: DNA content > 500 ng/mL, elastase activity > baseline - [ ] Anti-CarP antibody: specific binding to carbamylated proteins confirmed - [ ] TLR4 activation: ≥3-fold increase in NF-κB reporter over baseline - [ ] Dose-response relationship: EC50 for NETs and antibody enhancement - [ ] TAK-242 inhibition: ≥80% reduction in NET-induced activation - [ ] Cytokine confirmation: IL-8 or TNF-α release in supernatant - [ ] ≥3 biological replicates (independent neutrophil donors)

LINKED HYPOTHESES

Related Target

HTML iframe

<iframe src="http://scidex.ai/artifact/exp-ca7e1e3a-74a4-4039-adc3-b35982349661?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>

Markdown link

[TLR4 Activation Assay with NETs and Anti-CarP Antibodies](http://scidex.ai/artifact/exp-ca7e1e3a-74a4-4039-adc3-b35982349661)

Direct URL

http://scidex.ai/artifact/exp-ca7e1e3a-74a4-4039-adc3-b35982349661

Preview